KRTX News and Press, Karuna Therapeutics Inc. From 06/23/21

Company to initiate a Phase 2 trial evaluating KarXT in dementia-related psychosis in the first half of 2022 Results suggest that KarXT can be administered to elderly volunteers at doses which achieve xanomeline blood levels similar to those reported in the Phase 2 EMERGENT-1 ...

Halvorsen's 13F portfolio value decreased from $36.37B to $33.58B. The number of positions decreased from 96 to 94. Viking Global added Bank of America while reducing JPMorgan Chase and dropping Walt Disney. The top three positions are Microsoft, BridgeBio Pharma, and Fidelity Nat...

Healthcare sector and Real Estate Select Sector SPDR ETF (XLRE) gain of 1.92% and 1.88% respectively during the week outpaced S&P 500 gain of +0.40%.Looking at larger stocks (over $2B market capitalization), far and away the sector's top gainer was "meme stock" favorite ...

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector. The lower bar set for approval poses risk for Biogen in the out years. ...

Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment. Oncology companies get ready to present new data at the largest US oncology conference with potential fo...

Karuna Therapeutics (NASDAQ: KRTX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Karuna released 1Q21 earnings today, but quarterly financial performance is less important for a clinical-stage company such as Karuna. More ...

Karuna Therapeutics (KRTX): Q1 GAAP EPS of -$1.10 in-line.Cash, cash equivalents and investment of $571.3M.“This year is off to a very productive start, with the advancement of our early- and late-stage clinical programs, most notably the initiation and ongoing enrollment of three...

Three Phase 3 trials – EMERGENT-2, EMERGENT-3 and EMERGENT-4 – evaluating KarXT for the treatment of psychosis in adults with schizophrenia are currently enrolling On track to complete third cohort in Phase 1b trial evaluating KarXT in healthy elderly volunteers ...

Halvorsen's 13F portfolio value increased from $27.68B to $36.37B. The number of positions increased from 86 to 96. Viking Global added UnitedHealth, AbCellera Biologics, Walt Disney, and Palo Alto Networks while dropping Analog Devices, CME Group, Comcast, and Exact Sciences. The...

The following slide deck was published by Karuna Therapeutics, Inc. in conjunction with this event. For further details see: Karuna Therapeutics (KRTX) Presents At 10th Annual SVB Leerink Global Healthcare Conference